AMD101 Topical Ophthalmic Product (NVX101)
NVX101, our flagship topical ophthalmic product, has been developed to treat age-related macular degeneration (AMD). It features extended stability at room temperature and highly efficient delivery to the sub-retinal tissue by topical application. The sub-retinal tissue is the disease onset site of AMD. The product will be shortly prepared to undergo phase 1/2 clinical trials enrolling AMD patients to evaluate its efficacy and safety.
AMD101 Improved Topical Product (NVX102) and AMD101 Topical DR Products (NVX103)
These are next-generation topical ophthalmic products designed to enhance the efficacy and patient convenience of the existing AMD101 treatment for AMD and diabetic retinopathy (DR), respectively.